Share |
News

T-Ray Science, Inc. Grants Technology License To Toptica Photonics, Inc.


April 30, 2010 at 2:36 am

Vancouver, Canada: T-Ray Science, Inc. (TSX-V: THZ) (“T-Ray” or the “Company”) an emerging leader in the field of TeraHertz (“THz”) research, is pleased to announce that it has granted a Licensing Agreement to Toptica Photonics, Inc. (“Toptica”).

Toptica is a global market leader for THz sources and their applications, offering laser-based time and frequency domain sources. Part of the Toptica’s portfolio is offering customers a THz Standard Package plus Spectroscopy Kit product which uses a coherent detection technique for continuous wave (“cw”) THz signals. Under the terms of the Licensing Agreement, T-Ray will collect royalties on the sales of this product in the United States.

“The quality of Toptica’s products and their expertise in the field of THz imaging are world class,” said Thomas Braun, CEO of T-Ray.  “This is a significant endorsement of T-Ray’s cw THz platform technology.  While T-Ray continues to focus on developing its own skin cancer imaging device, we are forecasting additional Licensing Agreements to be concluded this year, positioning the Company for accelerated growth.”

T-Ray’s platform THz imaging technology has been shown to have numerous potential applications including homeland security, the detection of explosives and ceramic knives; process control in the paper, plastics, petro chemical and pharmaceutical industries; and medical imaging for detection of skin and other cancers.  THz waves are also a safe, accurate, and economical alternative to other scanning methods such as high frequency ultrasound, magnetic resonance imaging, and near-infrared imaging.  This emergent technology has the potential to revolutionize the way many diseases are diagnosed, and ultimately cured.  Numerous studies have shown that THz imaging can be used to image various cancers which continues to be the focus of T-Ray’s skin cancer imaging research and development.

About Toptica Photonics, Inc.

Since its founding in 1998, TOPTICA Photonics has stood for "highest precision in laser technology". The diode and fiber laser expertise of TOPTICA is world leading, including semiconductor amplification ultrafast pulse generation and frequency-conversion technologies. TOPTICA provides high-precision lasers as well as single-mode laser-related equipment to the forefront of atomic physics, microscopy, printing, optical disc manufacturing, metrology and many other applications.  A revolutionary new product range of ultra-fast fiber lasers is dedicated to highest precision applications and complements the cw emitting product range.  As an independent growing company, TOPTICA takes pride in offering its industrial customers dedicated systems with leading specifications and rugged, easy-to-use design for industrial 24/7 use.  Website:  www.toptica.com

 

About T-Ray Science, Inc.

The Company is developing a novel skin cancer imaging device which utilizes the unique properties of THz waves, and has exclusive rights to a platform technology originally developed at MIT that can be used for THz imaging in a broad range of applications.  T-Ray also has a Tablet Analyzer for counterfeit pharmaceutical applications such as drug authentication, offering a portable, low cost, easy to use, point of care solution, which is patented and in final production engineering with Sanmina SCI. 

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

For further information contact:

T-Ray Science, Inc.
Thomas Braun, President & CEO              
Telephone: 1-877-605-0507

Email: info@t-rayscience.com
Website:  www.t-rayscience.com

Caliber Capital
Tim McNulty, Investor Relations
Telephone: 778-327-6678

Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of THz based products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand.  These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

  Back to top